Glenmark Pharma Gains 3.62%: Bullish Momentum Returns

Glenmark Pharmaceuticals witnessed strong buying interest in today's session, surging 3.62% to close at ₹2,382. The stock has staged a sharp recovery from its recent October lows, indicating renewed buying interest and improving technical momentum. From a technical perspective, the stock has reclaimed all its key moving averages. It is trading above the 10 EMA (₹2,289.70), 20 EMA (₹2,288.50), 50 EMA (₹2,309.80), 100 SMA (₹2,292.80) and 200 SMA (₹2,224.70). This positive alignment reflects an improving short-term structure, while the position above the 200 SMA keeps the broader trend constructive. Momentum indicators are also supporting the recovery. RSI has climbed to 58.79, well above its average of 44.01, indicating strengthening bullish momentum. MACD has turned positive at 19.52, with a bullish crossover and expanding green histogram bars, suggesting that buying momentum is gaining traction. ADX stands at 30.21, indicating a relatively strong trend environment. However, traders should monitor whether the current momentum sustains in the coming sessions. The Bollinger Bands show the middle band near ₹2,261.30 and the upper band around ₹2,367.80. The latest close above the upper band highlights strong buying pressure, although short-term consolidation or volatility cannot be ruled out. Key Technical Levels: Immediate Support: ₹2,367–2,350 Strong Support: ₹2,310–2,290 Major Support: ₹2,225 Immediate Resistance: ₹2,400–2,420 Next Resistance: ₹2,500–2,543 My View: Glenmark Pharma is showing a promising technical recovery, backed by a bullish MACD crossover, improving RSI and a strong ADX reading. The reclaiming of all major moving averages is encouraging. A sustained move above ₹2,400–2,420 could open the door for further upside towards ₹2,500 and potentially ₹2,543. Traders should watch for sustained buying volumes and avoid chasing sharp price spikes. Disclosure: The analyst or his family does not have any position in the stock.